tbuckley/cabot-search huggingface dataset:
Using the Electronic Health Record to Understand and Minimize Overuse
Authors: Juliet Rumball-Smith, Paul G. Shekelle, David W. Bates
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.
Authors: Pier Luigi Zinzani, Enrico Derenzini, Cinzia Pellegrini, Luigi Rigacci, Alberto Fabbri, Federica Quirini, Vittorio Stefoni, Letizia Gandolfi, Lisa Argnani, Beatrice Casadei, Alessandro Broccoli, Alessandro Pulsoni, Marco Gobbi, Alessio Perrotti, Alfonso Zaccaria, Maria Teresa Voso, Maria Giuseppina Cabras, Amalia De Renzo, Michele Baccarani
Journal: Blood (2011)
Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT
Authors: Rosario Mazzola, Alba Fiorentino, Gioacchino Di Paola, Niccolò Giaj Levra, Francesco Ricchetti, Sergio Fersino, Umberto Tebano, Stefano Pasetto, Ruggero Ruggieri, Matteo Salgarello, Filippo Alongi
Journal: Journal of Thoracic Oncology (2017)
Impaired S Phase Arrest in AML Cells with a FLT3-ITD Treated with Clofarabine Allows Prolonged Drug exposure to Reverse the Chemoresistant Phenotype.
Authors: Claire Seedhouse, Martin Grundy, Shili Shang, John Ronan, Heather Pimblett, Nigel H. Russell, Monica Pallis
Journal: Blood (2009)
Pharmacokinetic and Pharmacodynamic Properties of SB1317, a Potent and Orally Active Multi-Kinase Inhibitor.
Authors: Pauline Yeo, P. Venkatesh, Evelyn Goh, Peizi Zeng, Lee S. New, Changyong Hu, Kanda Sangthongpitag, Anthony D. William, Kee C. Goh, Jeanette M. Wood, Ethirajulu Kantharaj
Journal: Blood (2007)
Advanced technique for biliary stricture diagnosis using endoscopic ultrasound (EUS)-guided hepaticogastrostomy
Authors: Nozomi Okuno, Kazuo Hara, Nobumasa Mizuno, Susumu Hijioka, Takamichi Kuwahara
Journal: Endoscopy (2017)

Postoperative benign biliary strictures are major adverse events following biliary surgery. Endoscopic retrograde cholangiography (ERC) is the standard treatment, but it is sometimes challenging in patients with surgically altered anatomy despite the development of balloon enteroscopy [1]. Recently, endoscopic ultrasound (EUS)-guided hepaticogastrostomy (EUS-HGS) has been reported as an effective salvage technique [2] [3]. We report a case in which, after formation of an EUS-HGS fistula, re-intervention and diagnosis of the cause of a stricture were easily performed using intraductal cholangioscopy (IDC; SpyGlass DS system; Boston Scientific Corp., Natick, Massachusetts, USA) through the hepaticogastrostomy route.
Author’s reply to Leng
Authors: Catherine M Otto
Journal: BMJ (2017)

Leng provides the website address for the National Institute for Health and Care Excellence (NICE) guidelines on statin use for primary prevention of cardiovascular disease and points out that linked tools support informed decision making by clinicians and patients.1 I agree that this website provides clear and useful information for patients and clinicians; I applaud all the work NICE does in this regard, which should serve as an example to other guideline developers.

My brief editorial mentioned only a few points about the use of statins for …
Repression of Mir-495, a Microrna Associated with Favorable Outcome of Acute Myeloid Leukemia Patients, Is Required for the MLL-Associated Leukemogenesis,
Authors: Xi Jiang, Hao Huang, Zejuan Li, Yuanyuan Li, Ping Chen, Chunjiang He, Stephen Arnovitz, Mary Beth Neilly, Janet D. Rowley, Jianjun Chen
Journal: Blood (2011)
MRP4 Expression and Platelet Activation in Children and Adolescents with Different Subtypes of Primary Thrombocythemia
Authors: Fiorina Giona, Marica Laurino, Isabella Massimi, Maria Luisa Guarino, Flavia Temperilli, Giovanna Palumbo, Sabrina Mariani, Deborah Marzella, Robin Foà, Fabio Maria Pulcinelli
Journal: Blood (2014)
The Use of Cyclosporine in Association with Chemotherapy As Induction Treatment in Patients with Acute Myeloid Leukemia (AML) and High Rhodamine Efflux at Diagnosis Results in Higher Complete Hematological Remission Rates, but Does Not Prolong Overall Survival
Authors: Luisa C A Koury, Lorena Lobo Figueiredo-Pontes, Belinda Pinto Simoes, Luciana C O Oliveira, Leandro F F Dalmazzo, Maria Carolina Tostes Pintão, Aglair B Garcia, Roberto Passetto Falcão, Eduardo Magalhães Rego
Journal: Blood (2015)
Prospective results of perioperative chemotherapy (PCT) with cisplatin and irinotecan for locally advanced gastric cancer.
Authors: Guilherme Luiz Stelko Pereira, Leonardo Gomes da Fonseca, Marcus Fernando Kodama Pertille Ramos, Ulysses Ribeiro, Gabriel Pereira, Marina Alessandra Pereira, Evandro Sobroza de Mello, Jorge Sabbaga, Paulo Marcelo Hoff
Journal: Journal of Clinical Oncology (2016)

147 Background: An overall survival (OS) benefit with PCT over surgery alone for locally advanced gastric cancer was seen in phase III trials. The best PCT regimen is uncertain and options based in infusional 5-FU or capecitabine have cost limitation in the context of Brazilian public health system. The combination of cisplatin and irinotecan is active in the metastatic setting, with no need of ambulatory infusion devices. The aim of this study is to evaluate safety and preliminary efficacy of this scheme as PCT. Methods: This prospective single arm study included patients (pt) with locally advanced gastric cancer, T3/T4 and/or evident lymph node involvement, to receive PCT cisplatin (30 mg/m2) and irinotecan (60 mg/m2) D1 and D8, each 21 days, in total of 6 cycles (Cy). Results: Between June/2011 and January/2014, 25 pt were included, with the following characteristics: 64 years (34-78) as median age; 10 (40%) pt with intestinal subtype and 10 with diffuse; 24% of cases were proximal gastric tumors; 20% had dysphagia and 24% bleeding signs before treatment. The median number of Cy before surgery was 3; 19 (76%) pt had surgery and 8 (32%) re-started Cy after surgery. Toxicity grade 3 or 4 was seen in 13 (52%) pt and 3 had unexpected arterial ischemic events. Radiologic progression occurred in 8 (32%) pt. Of the 21 tissue samples available, the expression of MLH-1, HER-2 (+++), p53, p16, Ki67 and EGFR was detected in 100% (21/21), 9.5% (2/21), 90.5% (19/21), 81% (17/21), 100% (11/21 &lt; 50% and 10/21 &gt; 50%) and 100% (10/21 +1/2 and 11/21 +3/4) of the cases, respectively. No correlation was seen between them and pathologic response. With a median follow up of 382 days, 13 (52%) pt were alive and the median OS was 15.2 (IC95% 4.9-24.5) months. In a univariate analysis, dysphagia, less than 3 Cy, progressive disease and neutrophil-to-Lymphocyte ratio (NLR) &gt; 2, were significantly related to shorter OS. In multivariate analysis, only NLR &gt; 2 (p = 0.019) and dysphagia were negatively impacting on OS (p = 0.02). Conclusions: Although PCT with cisplatin and irinotecan for evident locally advanced gastric cancer showed acceptable resection rate and local control, the overall prognosis was limited in this setting.
Dual endoscopic technique using through- and over-the-scope clips to close a colo-gastrocutaneous fistula due to a percutaneous gastrostomy tube
Authors: Alvaro Martínez-Alcalá Garcia, Joel Augustus, Krupali Thakar, Mohamad Shoreibah, Klaus Mönkemüller
Journal: Endoscopy (2017)

An 88-year-old woman with multiple morbidities, including end-stage renal disease, severely advanced dementia, type 2 diabetes mellitus, hypertension, and active bilobar pneumonia, who had undergone colonic resection and colostomy for a perforated diverticulum, followed by placement of a percutaneous endoscopic gastrostomy (PEG) tube 7 months previously, presented with malodorous fecal material coming out of her PEG tube.
Cortactin Expression Is Tightly Connected to B-Cell Chronic Lymphocytic Leukemia Aggressiveness
Authors: Cristina Gattazzo, Veronica Martini, Federica Frezzato, Valentina Trimarco, Elisa Ave, Samuela Carraro, Andrea Visentin, Gianpietro Semenzato, Livio Trentin
Journal: Blood (2012)
Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin’s Lymphomas.
Authors: Mehdi Hamadani, Kristie A. Blum, Patrick Elder, Thomas S Lin, Pierluigi Porcu, Craig C. Hofmeister, William Blum, Guido Marcucci, Don Benson, Steven Devine
Journal: Blood (2008)
Nuclear‐Targeted Multifunctional Magnetic Nanoparticles for Photothermal Therapy
Authors: Haibao Peng, Jing Tang, Rui Zheng, Guannan Guo, Angang Dong, Yajun Wang, Wuli Yang
Journal: Advanced Healthcare Materials (2017)

The pursuit of multifunctional, innovative, more efficient, and safer cancer treatment has gained increasing interest in the research of preclinical nanoparticle‐mediated photothermal therapy (PTT). Cell nucleus is recognized as the ideal target for cancer treatment because it plays a central role in genetic information and the transcription machinery reside. In this work, an efficient nuclear‐targeted PTT strategy is proposed using transferrin and TAT peptide (TAT: YGRKKRRQRRR) conjugated monodisperse magnetic nanoparticles, which can be readily functionalized and stabilized for potential diagnostic and therapeutic applications. The monodisperse magnetic nanoparticles exhibit high photothermal conversion efficiency (≈37%) and considerable photothermal stability. They also show a high magnetization value and transverse relaxivity (207.1 m m −1 s −1 ), which could be applied for magnetic resonance imaging. The monodisperse magnetic nanoparticles conjugated with TAT peptides can efficiently target the nucleus and achieve the imaging‐guided function, efficient cancer cells killing ability. Therefore, this work may present a practicable strategy to develop subcellular organelle targeted PTT agents for simultaneous cancer targeting, imaging, and therapy.
Role of GSK3 in Multiple Myeloma Cell Growth and Survival.
Authors: Francesco A. Piazza, Carmela Gurrieri, Gino Chioetto, Anna Colpo, Luca Bonanni, Barbara Montini, Laura Quotti Tubi, Marianna Gnoato, Samuela Carraro, Anna Cabrelle, Livio Trentin, Renato Zambello, Gianpietro Semenzato
Journal: Blood (2007)
Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Jae-Sook Ahn, Deok-Hwan Yang, Joon Ho Moon, Sang Kyun Sohn, Sung-Hoon Jung, Soo-Young Bae, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2011)
Early In Vivo Depletion of Suicide Gene-Modified T-Lymphocytes Transplanted in Conjunction with CD34+ Enriched Blood Stem Cells May Be Associated with an Increased Risk of Secondary Graft Failure.
Authors: Boris Fehse, Francis A. Ayuk, Nicolaus Kröger, Lubin Fang, Klaus Kühlcke, Marion Heinzelmann, Tatjana Zabelina, Axel A. Fauser, Axel R. Zander
Journal: Blood (2004)
A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.
Authors: Deborah A. Casale, Nancy L. Bartlett, David D. Hurd, Francine Foss, Barbara Pro, Lubomir Sokol, Ronald Lieberman, Hammershaimb Luz
Journal: Blood (2006)
CH50 Activity Correlates with Residual Intravascular Hemolysis in Pts with Paroxysmal Nocturnal Hemoglobinuria Treated by Eculizumab
Authors: Regis Peffault de Latour, Veronique Fremeaux-Bacchi, Raphael Porcher, Paula Rodriguez-Otero, Stephane Roncellin, Sarah Abbes, Gerard Socie
Journal: Blood (2012)
Role of Anemia in Survival of Elderly Aggressive Non-Hodgkin’s Lymphoma Patients Following Chemotherapy.
Authors: Pier Luigi Zinzani, Monica Tani, Anna Lia Molinari, Giuseppe Visani, Patrizia Gentilini, Luciano Guardigni, Vitorio Stefoni, Lapo Alinari, Enrica Marchi, Annalisa Gabriele, Gerardo Musuraca, Maria Paola Fina, Michele Baccarani
Journal: Blood (2004)
Clinical Evaluation of a New Functional, Plasma-Based Assay for the Detection of Factor V Leiden - the Pefakit® APC-R Factor V Leiden Assay.
Authors: Debra A. Hoppensteadt, Josephine Cunanan, Jeanine M. Walenga, Jawed Fareed, Marianne Wilmer, Michael Janssen
Journal: Blood (2004)
The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.
Authors: Simone Boehrer, Lionel Ades, Thorsten Braun, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, Genevieve Le Roux, Claude Gardin, Antoine Martin, Stephane de Botton, Pierre Fenaux, Guido Kroemer
Journal: Blood (2007)
Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)
Authors: Cristina Castilla-Llorente, Felipe de Arriba, Virginia Pérez-Andreu, Maria Victoria Mateos, Rocio González-Conejero, José Rivera Pozo, Albert Oriol, Joaquin Martínez-López, Ana Isabel Teruel, Raquel de Paz, José García-Laraña, Enrique Bengoechea, Alejandro Martín, Joaquín Díaz-Mediavilla, Luis Palomera, Yolanda Gonzalez, Jose Mariano Hernández, Anna Sureda, Jose Luis Bello, Joan Bargay, Francisco Javier Peñalver, Maria Luisa Martin Mateos, María Teresa Cibeira, Juan José Lahuerta, Joan Blade, Jesús F. San Miguel
Journal: Blood (2011)
Evaluation of the expression levels of S100A2 mRNA in renal cell carcinoma.
Authors: Takayuki Sugiyama, Tatsuya Takayama, Miki Miyazaki, Fumitake Kai, Naohiro Takaoka, Hiroshi Furuse, Soichi Mugiya, Seiichiro Ozono
Journal: Journal of Clinical Oncology (2012)

457 Background: The human S100 proteins are a calcium-binding protein comprising around 20 sort, at least 16 of these genes included pseudogenes are clustering to chromosome 1q21 , known as the epidermal differentiation complex. We have reported that S100A1 and A10 are expressed in human renal cell carcinoma (RCC) (Teratani T et al; Cancer Lett 2002, Teratani T, et al; BBRC 2002, Domoto, et al Cancer Sci. 2007). Diminished expression of S100A2 has been reported in some kinds of cancers (ex. lung, breast, prostate), but not reported in renal cell carcinoma (RCC). The aim of the present study is to evaluate the expression level S100A2 mRNA in human renal cell carcinoma. Methods: Sixty-one patients, pathologically diagnosed for clear cell RCC performed nephrectomy, were used in this study. Genomic DNA and RNA were extracted from RCC part and matched normal part in each patient. First-strand cDNA was synthesized from 2 micrograms RNA using Superscript-2 reverse transcriptase (Invitorgen), and reverse transcription polymerase chain reaction (RT-PCR) were performed using specific primers for S100A2. We also check the CpG methylation in the promoter region of the S100A2 gene using COBRA assay (combined bisulfite restriction analysis). Results: 45 cases (73%) showed decreased S100A2 expression in RCC parts. In53 cases of clear cell RCC, S100A2 expression decreased in fourty-two (79%) cases. In contrast clear cell RCC, 5 cases showed expression S100A2 in non-clear RCC (8cases; 62%), and 2 cases of clear cell RCC in VHL disease patients also had expression of S100A2. 30 cases of clear cell RCC were used in COBRA assay, S100A2 methylation were seen in all cases. Conclusions: Diminished expression of S100A2 is frequently shows in RCC, especially clear cell RCC. It suggests that property of clear cell RCC is different from other type of RCC.
Revisiting the Definition of Bronchopulmonary Dysplasia
Authors: Tetsuya Isayama, Shoo K. Lee, Junmin Yang, David Lee, Sibasis Daspal, Michael Dunn, Prakesh S. Shah
Journal: JAMA Pediatrics (2017)

<h3>Importance</h3> Several definitions of bronchopulmonary dysplasia are clinically used; however, their validity remains uncertain considering ongoing changes in the panoply of respiratory support treatment strategies used within neonatal units. <h3>Objective</h3> To identify the optimal definition of bronchopulmonary dysplasia that best predicts respiratory and neurodevelopmental outcomes in preterm infants. <h3>Design, Setting, and Participants</h3> Retrospective cohort study at tertiary neonatal intensive care units. Preterm infants born at less than 29 weeks’ gestation between 2010 and 2011 who were admitted to neonatal intensive care units participating in the Canadian Neonatal Network and completed follow-up assessments in a Canadian Neonatal Follow-Up Network clinic at 18 to 21 months. <h3>Exposures</h3> Various traditional bronchopulmonary dysplasia criteria based on respiratory status at different postmenstrual ages. <h3>Main Outcomes and Measures</h3> Serious respiratory morbidity, neurosensory impairment at 18 to 21 months of age, and a composite outcome of respiratory or neurosensory morbidity or death after discharge. Adjusted odds ratios (AORs) and 95% CIs were calculated. <h3>Results</h3> Of 1914 eligible survivors, 1503 were assessed (mean gestational age was 26.3 weeks; 68% were white, 9% were black, and 23% were other race/ethnicity), 88 had serious respiratory morbidity, 257 infants had neurosensory impairment, and 12 infants died after discharge. Definitions using oxygen requirement alone as the criterion at various postmenstrual ages were less predictive compared with those using the criterion of oxygen/respiratory support (RS) (receiving supplemental oxygen and/or positive-pressure RS); among those, oxygen/RS at 36 weeks had the highest AOR and area under the curve (AUC) for all outcomes. Further analyses of oxygen/RS at each week between 34 and 44 weeks’ postmenstrual age indicated that the predictive ability for serious respiratory morbidity increased from 34 weeks (AOR, 1.8; 95% CI, 0.9-3.4, AUC, 0.721) to 40 weeks (AOR, 6.1; 95% CI, 3.4-11.0; AUC, 0.799). For serious neurosensory impairment, the AOR and AUC at 40 weeks’ PMA (AOR, 1.5, 95% CI, 1.0-2.1; AUC, 0.740) were only marginally below their peak values at 37 weeks’ PMA (AOR, 1.8; 95% CI, 1.3-2.6; AUC, 0.743). <h3>Conclusions and Relevance</h3> Defining bronchopulmonary dysplasia by the use of oxygen alone is inadequate because oxygen/RS is a better indicator of chronic respiratory insufficiency. In particular, oxygen/RS at 40 weeks’ PMA was identified as the best predictor for serious respiratory morbidity, while it also displayed a good ability to predict neurosensory morbidity at 18 to 21 months.
Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy
Authors: Fabio Efficace, Michele Baccarani, Massimo Breccia, Francesco Cottone, Gianantonio Rosti, Giuliana Alimena, Giorgio Lambertenghi Deliliers, Claudia Baratè, Giorgina Specchia, Roberto Di Lorenzo, Luigia Luciano, Diamante Turri, Bruno Martino, Fabio Stagno, Melissa Dabusti, Micaela Bergamaschi, Anna Rita Scortechini, Maria Pina Simula, Luciano Levato, Carmen Fava, Dino Veneri, Simona Sica, Alessandro Rambaldi, Marco Vignetti, Franco Mandelli
Journal: Blood (2012)
Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations
Authors: Joshua D. Campbell, Christopher Lathan, Lynette Sholl, Matthew Ducar, Mikenah Vega, Ashwini Sunkavalli, Ling Lin, Megan Hanna, Laura Schubert, Aaron Thorner, Nicholas Faris, David R. Williams, Raymond U. Osarogiagbon, Paul van Hummelen, Matthew Meyerson, Laura MacConaill
Journal: JAMA Oncology (2017)

<h3>Importance</h3> Lung cancer is the leading cause of cancer death in the United States in all ethnic and racial groups. The overall death rate from lung cancer is higher in black patients than in white patients. <h3>Objective</h3> To compare the prevalence and types of somatic alterations between lung cancers from black patients and white patients. Differences in mutational frequencies could illuminate differences in prognosis and lead to the reduction of outcome disparities by more precisely targeting patients’ treatment. <h3>Design, Setting, and Participants</h3> Tumor specimens were collected from Baptist Cancer Center (Memphis, Tennessee) over the course of 9 years (January 2004-December 2012). Genomic analysis by massively parallel sequencing of 504 cancer genes was performed at Dana-Farber Cancer Institute (Boston, Massachusetts). Overall, 509 lung cancer tumors specimens (319 adenocarcinomas; 142 squamous cell carcinomas) were profiled from 245 black patients and 264 white patients. <h3>Main Outcomes and Measures</h3> The frequencies of genomic alterations were compared between tumors from black and white populations. <h3>Results</h3> Overall, 509 lung cancers were collected and analyzed (273 women [129 black patients; 144 white patients] and 236 men [116 black patients; 120 white patients]). Using 313 adenocarcinomas and 138 squamous cell carcinomas with genetically supported ancestry, overall mutational frequencies and copy number changes were not significantly different between black and white populations in either tumor type after correcting for multiple hypothesis testing. Furthermore, specific activating alterations in members of the receptor tyrosine kinase/Ras/Raf pathway including<i>EGFR</i>and<i>KRAS</i>were not significantly different between populations in lung adenocarcinoma. <h3>Conclusions and Relevance</h3> These results demonstrate that lung cancers from black patients are similar to cancers from white patients with respect to clinically actionable genomic alterations and suggest that clinical trials of targeted therapies could significantly benefit patients in both groups.
Lactadherin as a Probe for Phosphatidylserine Exposure and as An Anticoagulant for the Procoagulant Activity in the Study of Stored Platelets.
Authors: Jin Zhou, Jinxiao Hou, Wen Li, Xiaoqian Zhang, Yueyue Fu, Huibo Li, Rui Xie, Zhuo Zhang, Gary E. Gilbert, Jialan Shi
Journal: Blood (2009)
Comparative in-Vitro Evaluation of the Myeloid Toxicity of Pentostatin and the Novel PNP-Inhibitor Forodesine.
Authors: Mario Schubert, Christian Wallenwein, Larissa Pietsch, Dan Ran, Isabel Taubert, Katrin Miesala, Patrick Wuchter, Volker Eckstein, Anthony D. Ho
Journal: Blood (2009)